No Data
No Data
No Data
No Data
No Data
Improved Revenues Required Before G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock's 27% Jump Looks Justified
G1 Therapeutics, Inc. (NASDAQ:GTHX) shareholders have had their patience rewarded with a 27% share price jump in the last month. The last 30 days bring the annual gain to a very sharp 47%. Althou
Simply Wall StApr 19 19:56
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate
GlobeNewswireApr 17 21:00
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
In the preceding three months, 5 analysts have released ratings for G1 Therapeutics (NASDAQ:GTHX), presenting a wide array of perspectives from bullish to bearish.The table below offers a condensed vi
BenzingaApr 12 22:02
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
TipRanksApr 12 18:05
Needham: Reiterates G1 Therapeutics (GTHX.US) rating and adjusted from buy to buy rating, target price is $12.00.
Needham: Reiterates G1 Therapeutics (GTHX.US) rating and adjusted from buy to buy rating, target price is $12.00.
Zhitong FinanceApr 12 18:01
G1 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 156.41% Needham → $12 Reiterates Buy → Buy 02/28/2024 156.41% Needham → $12 Reiterates Buy → Bu
BenzingaApr 12 17:58
No Data
No Data